Seagen and genmab announce fda accelerated approval for tivdak™ (tisotumab vedotin-tftv) in previously treated recurrent or metastatic cervical cancer

Bothell, wash. & copenhagen, denmark--(business wire)--seagen inc. (nasdaq: sgen) and genmab a/s (nasdaq: gmab) today announced that the u.s. food and drug administration (fda) has granted accelerated approval to tivdak™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (adc) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. tivdak is approved under the fda's accelerated approval progra
SGEN Ratings Summary
SGEN Quant Ranking